A Review of International Recommendations for the Diagnosis and Management of Chronic Urticaria

Lisa A. BECK\(^1\), Jonathan A. BERNSTEIN\(^2\) and Marcus MAURER\(^3\)

\(^1\)University of Rochester Medical Center, Department of Dermatology, Rochester, NY, USA; \(^2\)Allergy Section, Division of Immunology, Department of Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH, USA, and \(^3\)Department of Dermatology and Allergy, Charité – Universitätsmedizin Berlin, Berlin, Germany

Both spontaneous and inducible forms of chronic urticaria pose a significant economic burden and have an adverse effect on patients’ quality of life. The international guidelines and US practice parameters for the diagnosis and management of chronic urticaria both recommend performing a thorough patient history and physical examination, conducting limited routine laboratory testing, and taking a stepwise approach to treatment. These documents differ in several areas, such as the order of diagnostic procedures and the treatment for patients non-responsive to standard dose H\(_1\)-antihistamines. Patients with chronic urticaria who visit a specialist have typically been treated with second-generation H\(_1\)-antihistamines – the recommended first-line treatments. The advantages and disadvantages of each treatment option should be taken into consideration when selecting therapies beyond H\(_1\)-antihistamines. Greater awareness of the international guidelines and US practice parameters will likely improve the quality of care for patients with chronic urticaria.

Key words: chronic spontaneous/idiopathic urticaria; physical urticaria; inducible urticaria; wheal; hives; guidelines.

Accepted Jun 15, 2016; Epub ahead of print Jun 28, 2016


Corr.: Lisa A. Beck, MD, University of Rochester Medical Center, School of Medicine and Dentistry, 601 Elmwood Ave, Box 697, Rochester, NY 14642, USA. E-mail: lisa_beck@urmc.rochester.edu

Urticaria is characterized by the presence of wheals (hives), angioedema or both, and is considered chronic if symptoms are present for 6 weeks or longer (1, 2). Understanding the clinical manifestations associated with chronic urticaria (CU) and its subtypes, and the available treatments will improve diagnosis and better guide clinical management. Therefore, the objective of this article is to highlight the burden of CU, provide evidence-based recommendations to obtain an accurate diagnosis, and outline management strategies.

DISEASE OVERVIEW

CU can be broadly divided into urticarias, characterized by the spontaneous onset of signs and symptoms, or inducible/physical urticaria, for which signs and symptoms arise following exposure to specific eliciting factors such as sustained pressure (delayed pressure urticaria) or hot or cold environments (heat- and cold-contact urticaria, respectively) (1, 2). It is possible, and in fact quite common, that two or more forms of CU coexist in the same patient (1, 2).

Differences in terminology exist between the international guidelines and the US practice parameters (1, 2). The international guidelines recognize two subtypes of CU: chronic spontaneous urticaria (CSU) and inducible urticaria (1). The US practice parameters include CU with physical triggers, CU for which a cause may be found, and chronic idiopathic urticaria (CIU; including autoantibody-associated urticarias) (2). The terms CSU and CIU are essentially synonymous in most cases and, as such, the term CSU is primarily used in this review because many cited studies were conducted outside of the US.

Although the pathology of CU is not fully understood, it is likely that mast cells, basophils, histamine, and other mediators play a key role (Fig. 1) (3–6). The release of histamine and other pro-inflammatory factors following degranulation of mast cells is regarded as the “final common pathway” in both physically induced CU and CSU, and forms the basis of H\(_1\)-antihistamines as the first-line therapy for CU (4). However, the causative factors leading to degranulation of tissue-resident mast cells or basophils are less clear and likely differ between physically induced CU and autoimmune CU. The autoimmune response is thought to involve autoreactive IgE antibodies against auto-allergens, or autoreactive IgG antibodies against the mast cell (or basophil) high-affinity receptor FcεRI, IgE, or both (4). The concept of a central role for IgE and FcεRI in priming mast cells (or basophils) for degranulation has led to the investigation of novel treatments, such asomalizumab. In the US practice parameters, CIU is considered to have an autoimmune basis in many, but not all, patients, while other underlying causes of CIU that have been proposed, include infections, food intolerance and autoallergy (2, 4). The international guidelines also identify potential causes such as autoimmune disease, hypersensitivity reactions to food and drugs, and infections, but do not differentiate the etiology of CU subtypes (1).

Based on a survey conducted in Germany, the lifetime prevalence of CU was estimated to be 1.8% (7). CSU...
consistently accounts for the majority of cases of CU, with reported estimates ranging from 66% to 93% (8). Many patients remain symptomatic beyond one year, with up to 14% of patients continuing to experience recurrent outbreaks of symptoms for longer than 5 years (9, 10).

The impact of CU on quality of life (QoL) was found to be similar to the impact of ischemic heart disease in patients awaiting coronary artery bypass grafting and greater than respiratory allergy in patients with perennial rhinitis and intermittent asthma (11, 12). Impairment of QoL due to CU was reportedly worse than or similar to that observed with other skin diseases, including psoriasis, acne, or atopic dermatitis (13–15). The impact of CU on QoL has recently been highlighted in an Italian narrative medicine project (16). Based on data from 2004 to 2006, the mean yearly direct and indirect costs of CSU in the US were estimated to be $244 million (17). Of the total annual cost, medication accounted for 62.5% and wages lost because of travel to outpatient visits/absences from work accounted for 15.7% (17).

Impairment of QoL in CSU patients who also have a psychiatric comorbidity (e.g. depression and/or anxiety) has been reported to be greater than in those without a psychiatric diagnosis (18, 19). In a large population-based study, autoimmune diseases (predominantly thyroid disorders) were significantly more common in patients with CU than in control patients without a diagnosis of CU (20).

**ROLE OF SPECIALISTS**

Well-designed clinical studies have provided evidence for the use of approved doses of second-generation H₁-antihistamines as the first-line therapy for CU, and there is broad consensus for such a treatment approach (1, 2). Despite this, a German survey of 776 physicians (43.0% dermatologists, 28.7% pediatricians, and 27.5% general practitioners [GPs]) carried out in 2009 revealed that a considerable proportion reported using sedating antihistamines (23.0%) and oral corticosteroids (17.9%) as the first choice (21). Unfamiliarity with patient management guidelines may have contributed to this observation: physicians who indicated that they were aware of the international guidelines were significantly less likely to use sedating antihistamines than those who were unaware of them (21). Although only one-third of physicians responded that they knew of the international guidelines, there was greater knowledge among dermatologists (50.6%) than among pediatricians (24.2%) and GPs (12.6%) (21). It is noteworthy that in Germany, it is common place for dermatologists to be dual trained in allergy. Therefore, it is possible that knowledge of patient management guidelines among US-based dermatologists may be lower than among German dermatologists.

A cross-sectional survey of 180 healthcare providers in the UK conducted in 2014 reported that 48 of 64 (75.0%) dermatologists used guidelines for the diagnosis and management of CU, compared with 50 of 55 (90.9%) allergists and immunologists. Among these physicians who reported using guidelines, the 2013 international guidelines were cited by a greater proportion of allergists/immunologists (52.1%) than dermatologists (10.6%) (22). Despite this, and in contrast to the earlier German survey, all physicians reported using second-generation antihistamines as first-line treatment.

In an online survey that assessed 80 Canadian dermatologists’ perspectives of CU, most were using H₁-antihistamines as a first-line treatment (96.8%). Interestingly, 16.1% of respondents reported > 50% of their patients had refractory CU, and the perceived next best
add-on therapy was not consistent. Overall satisfaction with diagnosis and management of CU was low, but most (59.7%) were not familiar with the international guidelines (23).

The knowledge gap is further illustrated by data from a case-series study of referred patients in Denmark who, at presentation to a specialist urticaria clinic in 2009–2011, were generally treated with insufficient doses of second-generation H₁-antihistamines (24). The disease management guidelines also show clear consensus on up-dosing second-generation H₁-antihistamines in CSU patients who have failed to show sufficient response; however, it was again apparent from the German survey that compared with GPs and pediatricians, dermatologists had the most experience with up-dosing these drugs (21). Nonetheless, even following standard and high doses of second-generation H₁-antihistamines a number of patients remain antihistamine-resistant, and it is likely that dermatologists are best positioned to manage these patients. In the German physician survey, dermatologists were found to have more experience of alternative treatment options, such as dapsone and other immunosuppressants, which are of major importance in patients who do not respond to higher doses (21). Understanding what the treatment options are for patients with moderate-to-severe CSU is critical not only for the dermatologists for whom 65.5% of their patients fall into this severity, but also for GPs and pediatricians (with 49.8% and 46.1% patients with moderate-to-severe CSU, respectively) (25).

## DIAGNOSIS AND TREATMENT GUIDELINES

The international guidelines and US practice parameters both recommend a thorough patient history and physical examination, limited routine laboratory testing, and a stepwise approach to treatment, but they differ in several areas (Tables I, II) (1, 2). For example, the US practice parameters place greater emphasis on the limitations of laboratory testing, discuss treatment options not present in the international guidelines, and do not focus on evaluating treatment success (1, 2).

It is worth noting that key similarities and differences between these two important guideline documents have also been considered previously (26). There are few major differences, but where they do occur, it tends to be driven by differences in expert opinion where guidance is provided in the absence of strong scientific evidence (26). Needless to say global consensus activities relating to urticaria are ongoing.

## DIAGNOSIS

The characteristic skin finding of CU is the presence of hives that typically manifest as edematous, pink or red, pruritic wheals of variable size and shape, and lack any epidermal changes such as scale/crust. Individual lesions are evanescent and typically fade within 24 h. Angioedema generally involves swelling of the lower dermis and subcutis, with frequent involvement of the proximal mucus membranes (ocular or lip edema) or se-

| Tests for the identification of underlying causes of CSU based on patient history | Based on patient history (in no preferred order): test for infectious diseases (e.g. Helicobacter pylori), type I allergy, functional autoantibodies, thyroid hormones and autoantibodies, tryptase as indication of severe systemic disease; perform skin tests including physical tests and/or lesional skin biopsy; trial pseudoallergen-free diet for 3 weeks; conduct ASST
| Tests for differential diagnosis | Depending on patient history:

- If inflammatory disease is strongly suspected, consider: ESR and/or CRP level; testing for paraproteinemias (adults); screening for neuropathic-rich infiltrates in skin biopsy; performing gene mutation analysis for hereditary periodic fever syndromes.
- If HAE is suspected, test for complement C4, C1-INH levels and function, and C1q and C1-INH antibodies.
- If history suggests HAE and former tests are unremarkable, perform gene mutation analysis.
- If mean wheel duration is >24 h, perform biopsy of lesional skin to assess for signs of urticarial vasculitis (damage to small vessels in the papillary and reticular dermis and/or fibrinoid deposits in perivascular and interstitial locations)

| US practice parameters for the diagnosis and management of CU (2) | No major differences from international guidelines

Testing should be selective. For patients with CU without atypical features consider: CBC with differential, ESR and/or CRP level, liver enzymes, TSH; clinical utility of using these tests routinely has not been established

Limited laboratory testing, routine testing rarely yields clinically significant findings

Based on patient circumstances, history and physical examination consider:

- Skin biopsy
- Physical challenge tests
- Complement activity tests
- Stool analysis (ova and parasites)
- Urinalysis
- Hepatitis B and C serologies
- Antinuclear antibody, rheumatoid factor and/or anti-citrullinated protein
- Cryoglobulin levels
- Serologic and/or skin testing for immediate hypersensitivity
- Thyroid autoantibodies to: TSH receptor, thyroglobulin, thyroid peroxidase, and sodium/iodine symporter
- Serum protein electrophoresis

ASST: autologous serum skin test; C1-INH, C1-inhibitor; CBC: complete blood count; CRP: C-reactive protein; CSU: chronic spontaneous urticaria; EAACI: European Academy of Allergy and Clinical Immunology; EDF: European Dermatology Forum; ESR: erythrocyte sedimentation rate; GA/LEN: Global Allergy and Asthma European Network; HAE: hereditary angioedema; TSH: thyroid-stimulating hormone; WAO: World Allergy Organization.
Cholinergic urticaria

Exercise and hot bath provocation

Aquagenic urticaria

Wet cloth (body temperature) for 20 min

Water compress (35°C) applied to the upper body for 30 min

Test with vortex

Vibratory angioedema (97)

US practice parameters for the diagnosis and management of CU (2)

Apply cold stimulus (e.g. ice cube on forearm) and observe for wheal-and-flare reaction during skin rewarming

Challenge with a 15 lb (6.8 kg) weight suspended over shoulder for 10–15 min and monitor for angioedema development

Does not include as a separate subtype; patients with lesions in response to heat are categorized as having cholinergic urticaria

Phototest to various wavelengths of light

Stroke skin with firm object (e.g. tongue blade or other instrument with a firm edge) or a dermographometer

Water compress (35°C) applied to the upper body for 30 min

Provocative challenges that increase core body temperature (e.g. exercise, hot water immersion, or methacholine intradermal challenge)

Exercise challenge in a setting prepared for anaphylaxis management

Exercise challenge in a setting prepared for anaphylaxis management

Cutaneous prick test

Cutaneous prick test, skin test with immediate readings, for example prick test

Table II. Comparison of recommendations for confirming the relevance and threshold of triggers for inducible chronic urticaria (CU) in the EAACI/GA²LEN/EDF/WAO international guidelines and the US practice parameters for the diagnosis and management of CU

TREATMENT

Approved doses of second-generation H₁-antihistamines are the universally recommended first-line therapy for CU (1, 2), based on demonstrated efficacy in double-blind clinical studies (27–31). Because there are not enough comparative studies to identify a preferred agent (1, 2) and individual patients may respond differently to treatment (32), selection must be based on physician/patient discretion. A progressive increase to up to 4-fold the standard dose is recommended for patients who do not respond to approved doses (1, 2). Studies have shown that increasing the antihistamine dose may improve control of CU symptoms, but data for some antihistamines are limited and conflicting (33–41).

In our experience, approximately 50% of all patients with CSU respond to antihistamines at standard doses and another 10–25% will respond with up-dosing, but at CSU referral centers as many as 96% of patients have failed antihistamines even at high doses (42). However, it is important to confirm that the patients have been compliant with the treatment dose and schedule, and that their response is inadequate (43–45). As indicated by both the international guidelines and US practice parameters, additional treatment options are available for patients who do not respond to monotherapy (Fig. 2) (2). Although not included in the international guidelines, the US practice parameters recommend adding an additional second-generation H₁-antihistamine and/or H₂-antagonist to H₁-antihistamine therapy (step 2). Data comparing the efficacy and safety of combination therapy versus up-dosing of a single agent are scarce (46, 47), but, as a general principle, it is likely to be safer to adjust the dosing of a single drug rather than complicating management with several antihistamine classes (48).

First-generation antihistamines have similar efficacy, but greater sedation and impairment compared with second-generation antihistamines, and should therefore be used with caution (1, 2, 28, 29). The US practice parameters recommend the use of first-generation antihistamines at bedtime in order to reduce daytime impairment (2); however, they have been shown to frequently lead to daytime somnolence, sedation, drowsiness, fatigue and impaired concentration and memory, especially if...
The treatment of CU as monotherapy or in combination with antihistamine therapy, but they have considerable sedating effects (1, 2). Compared with other antidepressants taken late at night (49). H1-antihistamines, specifically cimetidine, used in combination with H1-antihistamines have shown a limited additive effect, and are, therefore, no longer recommended by the international guidelines (50–52).

In the international guidelines and the US practice parameters, patients are considered to have refractory CU based on the absence of clinical response to antihistamine therapy. However, the international guidelines consider the threshold to be up to 4 times the approved dose of antihistamines, whereas the US practice parameters consider it to be maximal combination antihistamine therapy (1, 2). Similarly, the treatment course for patients non-responsive to antihistamine treatments differs between the international guidelines and US practice parameters (1, 2). For these patients, a number of treatment options are available, several of which have evidence from at least one double-blind randomized controlled trial that supports their use (Table IV) (1, 2, 45, 53, 54).

Oral corticosteroids are frequently used in patients with CU not adequately controlled with antihistamine therapy, yet no controlled study has been performed (2, 55). A large retrospective study found that 50% of patients with antihistamine-resistant CU treated with a single course of prednisone (25 mg/day for 3 days, escalated to 12.5 mg/day for 3 days and 6.25 mg/day for 4 days) had a remission, and an additional 9% responded after a second course (56). The main concern with the use of corticosteroids is the risk of adverse effects, thus only short-term use to help manage exacerbations should be considered (1, 2).

Leukotriene-modifying agents (LTMAs) such as montelukast and zafirlukast, are reportedly effective for the treatment of CU as monotherapy or in combination with H1-antihistamines, with the strongest evidence for montelukast (10 mg/day), although the treatment effect observed was small (57–65). Results of clinical studies have been inconsistent; some showing superiority (60, 64, 65), and others demonstrating inferior responses from LTMAs compared with antihistamines (61), or even a lack of efficacy compared with placebo (66).

Agents with H1- and/or H2-antagonist activity such as hydroxyzine, cyprophedrine, or doxepin are also options for patients whose symptoms do not respond to prior antihistamine therapy, but their sedative effects (1, 2). Compared with other antidepressants

Table III. Conditions to consider in the differential diagnosis of chronic urticaria (CU)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Differentiating features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anaphylaxis</td>
<td>Generalized wheals/angioedema and involvement of multiple organs other than skin, such as pulmonary tract, gastrointestinal, nervous, or cardiac systems</td>
</tr>
<tr>
<td>Autoimmune thyroid disease</td>
<td>Thyroid orbitopathy, swelling of area between upper eyelids and eyebrows, and appearance of angioedema of upper eyelids</td>
</tr>
<tr>
<td>Bullous pemphigoid</td>
<td>Pruritic papules and plaques that develop into tense subepidermal blisters</td>
</tr>
<tr>
<td>CI-inhibitor deficiencies</td>
<td>Recurrent angioedema without wheals</td>
</tr>
<tr>
<td>Contact dermatitis</td>
<td>Persistent angioedema of lips; symptoms associated with exposure to stimulus (e.g. poison ivy, nickel)</td>
</tr>
<tr>
<td>Cutaneous and systemic lupus erythematosus</td>
<td>Biopsy shows leukocytoclastic vasculitis</td>
</tr>
<tr>
<td>Cutaneous mastocytosis</td>
<td>Skin lesions that uricate when stroked</td>
</tr>
<tr>
<td>Food/insect allergies</td>
<td>Urticaria develops following exposure</td>
</tr>
<tr>
<td>Angioedema with ACE or DPP IV inhibitors (98)</td>
<td>Angioedema without urticaria including laryngeal edema that presents with very large lip edema and tongue edema; can present even after months or years of therapy</td>
</tr>
<tr>
<td>Polymorphous light eruption</td>
<td>Clustered pruritic papules and plaques appearing within minutes to hours of exposure to sunlight; duration of approximately several days</td>
</tr>
<tr>
<td>Urticarial vasculitis</td>
<td>Lesions do not blanch (e.g. petechial/purpuric), are more commonly associated with symptoms of burning or pain than pruritus; heal with residual hyperpigmentation; joint pain, fatigue, or shortness of breath possible; duration &gt;24 hours; diagnosis involves biopsy</td>
</tr>
<tr>
<td>Less common or uncommon</td>
<td></td>
</tr>
<tr>
<td>Autoimmune progesterone-associated dermatoses, including cataminal dermatoses</td>
<td>Develops 3–10 days before menses; can present with lesions that look like eczema, erythema multiforme, bullous disease, or folliculitis</td>
</tr>
<tr>
<td>Autoinflammatory syndromes: Familial cold-autoinflammatory syndrome</td>
<td>Erythematous papules and plaques that can last &gt;24 h, fever, arthralgia and conjunctivitis 1–2 days after exposure to cold, negative responses to cold challenge</td>
</tr>
<tr>
<td>Muckle-Wells</td>
<td>Renal abnormalities, progressive deafness</td>
</tr>
<tr>
<td>NOMID</td>
<td>Signs of bony overgrowth, mental retardation, papilledema</td>
</tr>
<tr>
<td>Hyper-IgD syndrome, TRAPS, PFAPA, PAPA</td>
<td>Present with fever</td>
</tr>
<tr>
<td>FMF</td>
<td>Erysipeloid-like lesions on lower extremities; fever, arthralgias, serositis without adenopathy; presents in patients of Mediterranean heritage; duration of approximately 3 days</td>
</tr>
<tr>
<td>Cryoglobulinemia</td>
<td>Palpable purpura/petechiae on lower extremities; brawny edema of lower legs</td>
</tr>
<tr>
<td>Episodic angioedema with eosinophilia (Gleich syndrome)</td>
<td>Episodic attacks of profound angioedema with weight gain</td>
</tr>
<tr>
<td>Schnitzler syndrome</td>
<td>Long-lasting urticarial wheals occurring in association with intermittent fevers, bone pain, arthralgias, myalgias, and IgM &gt; IgG gammopathy</td>
</tr>
<tr>
<td>Urticaria-like dermatoses of pregnancy: Gestational pemphigoid</td>
<td>Abrupt onset of pruritic papular urticaria, initially on trunk, becomes generalized and blisters</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| ACE: angiotensin-converting enzyme; CBC: complete blood count; DPP IV: dipeptidyl peptidase-4; FMF: familial Mediterranean fever; hyper-IgD: hyper-immunoglobulin D syndrome with periodic fever; NOMID: neonatal-onset multisystem inflammatory disease; PFAPA: periodic fevers with aphthous stomatitis, pharyngitis, and adenitis; PAPA: pyogenic arthritis, pyoderma gangrenosum, and acne syndrome; PUPPP: pruritic urticarial papules and plaques of pregnancy; TRAPS: tumor necrosis factor receptor-associated fever syndrome. Adapted from Bernstein et al. (2).
such as amitriptyline, nortriptyline, and mirtazapine, clinical evidence is strongest for doxepin (at doses from 10 mg to 25 mg 3 times daily) (2, 32, 67–69); however, sedation, electrocardiographic effects at doses >100 mg, and numerous drug–drug interactions may limit its use (2, 70, 71).

Of the available agents recommended for patients with refractory CU, omalizumab (Xolair®, Genentech, Inc.; San Francisco, CA), an anti-IgE antibody, has the most robust data supporting its use (45), and as of February 2016 is the only agent approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of adults and adolescents who have refractory CIU and CSU, respectively (72, 73). Although omalizumab (administered as subcutaneous injections every 4 weeks at doses of 150 mg, or 300 mg) has a favorable risk/benefit ratio and was well tolerated in clinical studies (74–76) it has infrequently been associated with anaphylaxis (72, 76). Omalizumab has also been shown to be an efficacious treatment alone or as an add-on therapy to H₁-antihistamine plus an H₂-antihistamine or LTMA, or a combination of these for patients with CIU refractory to antihistamine treatment in 3 Phase 3 studies (74–76). However, the cost of treatment, the requirement for subcutaneous administration in a physician’s office and anaphylaxis concerns may limit its use (2, 45).

In addition to omalizumab, both the international guidelines and the US practice parameters recommend consideration of cyclosporine A (CsA) for patients with refractory CU (1, 2). CsA is an immunosuppressant that has been shown to be an effective treatment for CU (at dosages of 3–5 mg/kg/day for up to 4 weeks) in placebo-controlled studies as a solo treatment and in combination with second-generation H₂-antihistamines (77, 78). Treatment with CsA is associated with a relatively high incidence of mild adverse effects including gastrointestinal disturbances, paresthesia and infections (77, 78); retrospective study showed that adverse effects were generally mild and transient for patients with CU using low-dose CsA (<3 mg/kg/day) for up to 10 years (79). However, long-term, low-dose CsA treatment is known to be associated with nephrotoxicity (80). Clinicians need to carefully consider whether CsA is an appropriate treatment option based in part on a patient’s comorbidities. For example, subjects with hypertension and/or renal insufficiency would not be a good candidate for CsA treatment. It is also important to be aware that there are clinically important differences in bioavailability between CsA preparations (2, 81, 82).

Additional anti-inflammatory agents and immunosuppressants can be considered for patients with refractory CU (2), but there is limited evidence supporting the use of these agents (44, 83, 84). Anti-inflammatory agents, including dapsone, sulfasalazine, hydroxychloroquine and colchicine, have limited evidence for efficacy in CU (2), but a recent double-blind, placebo-controlled study in patients with CSU indicates dapsone 100 mg/day led to a significant improvement of symptoms (85). It remains to be confirmed whether these agents are more effective in patients with neutrophil-rich urticaria. An open study reported that among CU patients with neutrophilic skin inflammation, 8 of 9 treated with colchicine and 3 of 3 treated with dapsone showed a response (2, 86). Other immunosuppressants to consider include tacrolimus, mycophenolate and methotrexate, but clinical evidence supporting their use is very low (2). Case reports suggest that the anti-CD20 biologic, rituximab, may also
provide some benefit (87). A recent publication assessing treatment response in relationship to CU characteristics may be useful for selecting treatment regimens (57). More studies, especially randomized controlled trials, are needed to confirm the clinical improvement seen with these off-label therapies, as well as comparative effectiveness studies of both FDA-approved and off-label therapies. There is still an unmet need for new, more effective therapies to treat patients with refractory CU and with this greater refinement of which CU sub-phenotypes will respond best to which therapy.

**EVALUATING TREATMENT SUCCESS**

The goal of CU treatment is to achieve substantial improvements in symptoms with limited adverse effects (1). It is important to measure the patient’s urticaria activity at baseline, and during subsequent visits to the clinic in order to objectivly assess the response to treatment(s).

The Urticaria Activity Score (UAS) is a validated tool (87, 89) that has been used frequently for measuring and monitoring disease activity in clinical studies of urticaria and clinical practice (1, 74–77, 90, 91). In the international guidelines, the sum of the patient-reported UAS over 7 days (UAS7) is the recommended approach for assessing treatment success in CSU (Table I) (1, 89, 94, 95). The UAS and CU-QoL instrument recommended for patients with a variety of skin conditions that has correlated positively and significantly with UAS (15, 88).

The Urticaria Control Test (UCT) is an alternative patient-reported instrument validated for retrospective assessment of any CU subtype using 4 questions (92). Visual analog scales can also be used to assess disease severity and response of symptoms to treatment that are difficult to measure objectively, such as itch intensity (93).

Because of the significant impact CU has on QoL, assessing QoL is an important aspect of monitoring disease activity (1). The Dermatology Life Quality Index (DLQI) is a validated 10-question tool to compare QoL in patients with a variety of skin conditions that has correlated positively and significantly with UAS (15, 88). The Chronic Urticaria Quality of Life Questionnaire (CU-QoL) is a validated QoL tool and the only disease-specific QoL instrument recommended for patients with CSU (1, 89, 94, 95). The UAS and CU-QoL should be used to measure the effects of change in CSU disease activity rather than non-validated tools (96).

**CONCLUSION**

CU is a complex disorder that has a substantial economic burden and a significant impact on patients’ QoL. A complete history and physical examination will ensure the accurate diagnosis of CU and will determine the extent of laboratory studies needed for each individual patient. Many patients may respond adequately to approved doses of second-generation H1-antihistamines, which should be first-line therapy. For those who do not achieve significant clinical improvement, the advice is to increase the dose of these non-sedating antihistamines to up to 4 times the approved dose. The authors recommend using one antihistamine in this category for the dose escalation rather than double the dose of two different second-generation antihistamines. During this dose escalation the addition of a sedating antihistamine in the evening can also be effective, but combining a non-sedating antihistamine and a sedating antihista-mine is not recommended by all experts or the EAACI/ GA²LEN/EDF/WAO guideline. If dose modulation of the first- and second-generation antihistamines do not significantly improve the CU and/or if the side effects needed to achieve this level of clinical improvement are

---

### Table IV. Agents with at least one double-blind randomized controlled trial supporting its use for patients with refractory chronic urticaria (CU) who are resistant to high-dose or combination antihistamine therapy

<table>
<thead>
<tr>
<th>Alternative agent</th>
<th>Typical dose</th>
<th>Onset of improvement</th>
<th>Estimated effectiveness</th>
<th>Evidence</th>
<th>Risk (pregnancy category)a</th>
<th>Laboratory monitoring</th>
<th>Costb</th>
<th>Induction of remissionc</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anti-inflammatory agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Montelukast 10 mg daily</td>
<td>2–4 weeks</td>
<td>Low</td>
<td>Multiple RCTs (mixed results) (61, 65)</td>
<td>Minimal (B)</td>
<td>None</td>
<td>$$</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>Dapsone 100 mg daily</td>
<td>1–6 weeks</td>
<td>Moderate</td>
<td>1 RCT (85)</td>
<td>Low-moderate (C)</td>
<td>Baseline: G6PD, CBC; LFT; Monthly: CBC, LFT &gt;6 months then periodically</td>
<td>$</td>
<td>Possible</td>
<td></td>
</tr>
<tr>
<td>Zafirlukast 20 mg twice daily (53)</td>
<td>Several days to 1 week (53)</td>
<td>Low</td>
<td>2 RCTs (negative results) (60, 66)</td>
<td>Minimal (B) (99)</td>
<td>None (53)</td>
<td>$$</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td><strong>Immunosuppressant agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclosporine A 3–5 mg/kg/day</td>
<td>1–7 days</td>
<td>High</td>
<td>2 RCTs (77, 78)</td>
<td>Moderate-high (C)</td>
<td>Every 2–4 weeks: BUN/ Cr, Mg, CsA Periodic: lipids, glucose</td>
<td>$$$</td>
<td>Possible</td>
<td></td>
</tr>
<tr>
<td><strong>Immunomodulatory agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Omalizumab 150–300 mg every 4 weeks</td>
<td>1–2 weeks</td>
<td>High</td>
<td>5 RCTs (74–76, 90, 101)</td>
<td>Low-moderate (B)</td>
<td>None</td>
<td>$$$</td>
<td>Unknown</td>
<td></td>
</tr>
</tbody>
</table>

aCategory B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women; Category C: animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks. bCost ratings are based on comparison with each agent with $ being the least expensive and $$$$ the most expensive. cInduction of remission that was based on reports of resolution of urticaria after therapy has been discontinued.

BUN: blood urea nitrogen; CBC: complete blood count; Cr: creatinine; CsA: cyclosporine A; G6PD: glucose-6-phosphate dehydrogenase; LFT: liver function test; Mg: magnesium; RCT: randomized controlled trial. Adapted from Khan (45).
unacceptable then one should consider the addition of omalizumab. If omalizumab fails, is not well tolerated or unavailable, alternate options should be considered: CsA, dapsone, colchicine, mycophenolate, sulfasalazine, rituximab or leukotriene antagonists. Of these options the evidence of clinical effectiveness is most robust for omalizumab and to a lesser extent CsA. The advantages and disadvantages of each of these options should be taken into consideration when selecting an appropriate therapy.

ACKNOWLEDGMENT

Conflicts of interest: LAB is a consultant for AbbVie, Array Biopharma, Celgene, Genentech, MedImmune, Novartis, and Regeneron. JAB has received research funding from Novartis and Genentech and is a speaker and consultant for Novartis and Genentech. MM is or recently was a speaker and/or advisor for FAES Farma, Almirall Hermal, Genentech, GlaxoSmithKline, Merckle Recordati, Novartis, Sanofi Aventis, Merck Sharp & Dohme, Moxie, Takeda, UCB, and Uriach.

Disclosure and funding sources: Medical writing and editorial assistance in the development of this manuscript were provided by Sarah Thornburg at JK Associates, Inc., Conshohocken, PA, USA, a part of the Fishawack Group of Companies, and this service was supported by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA and Genentech, Inc., South San Francisco, CA, USA.

REFERENCES

27. Monroe EW. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria: a 6-week, randomized, double-blind, placebo-controlled, parallel,

47. Staevska M, Gugutkova M, Lazarova C, Kralimarkova T, Schulz S, Metz M, Siepmann D, Luger TA, Maurer M, Stän

46. Schulz S, Metz M, Siepmann D, Luger TA, Maurer M, Stän

44. Kameyoshi Y, Tanaka T, Mihara S, Takahagi S, Niimi N, Hide


